| CTAS |
Report |
Adjusted diluted EPS (Q4 FY26) |
BEAT |
pred ~$1.26 vs. cons $1.24 |
MEDIUM |
| CTAS |
Report |
Total revenue (Q4 FY26) |
IN-LINE |
pred ~$2.90B vs. cons $2.88B |
MEDIUM |
| CTAS |
Report |
Total company organic growth rate (Q4 FY26) |
IN-LINE |
pred ~7.8% vs. cons 8.1% |
LOW |
| CTAS |
Guide |
FY2027 initial revenue guidance (standalone, ex-UniFirst) |
BETTER |
guide ~$12.05B vs. cons $12.00B (FY2027) |
LOW |
| CTAS |
Guide |
FY2027 initial adjusted EPS guidance (standalone, ex-UniFirst) |
BETTER |
guide ~$5.40 vs. cons $5.35 (FY2027) |
LOW |
| CTAS |
Guide |
UniFirst deal close timeline / FTC Second Request commentary |
UNCHANGED |
guide ~2H2026 close vs. cons 2H2026 close (FY2027) |
LOW |
| CTAS |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.2% |
— |
LOW |
| CTAS |
Return |
5-day cumulative residual |
-0.8% (FADE) |
Q4 print itself is largely de-risked (guidance-implied EPS/revenue already tightly bracketed by consensus), so any Day-1 pop from a modest EPS beat is likely to fade as investors digest the first standalone FY2027 guide, which should show organic growth decelerating further off the tough FY26 comp (management already flagged high-7% Q4 organic vs. last year's 9% peak) and continued ambiguity on UniFirst timing given the still-open FTC Second Request. Analysts are likely to trim out-year (FY27) organic growth/margin assumptions even after a Q4 beat, and the stock's recent sharp recovery into the print (+12% off the spring trough) raises 'sell-the-news' risk if no incremental positive FTC/deal color is offered, pulling the idiosyncratic return back down over the week. |
LOW |